SGLT2 inhibitors in 2025: a shift from glycemic control to cardiorenal protection

Czech version

Authors: Adriana Ilavská
Authors‘ workplace: Medispektrum s. r. o., Bratislava
Published in: Diab Obez 2026; 26(1): 49-51
Category: News

Overview

At the EASD Annual Meeting 2025, sodium-glucose cotransporter 2 (SGLT2) inhibitors were presented as an established pillar of cardiorenal protection with effects extending beyond glycemic control. Data from randomized clinical trials and observational analyses confirm their significance in reducing hospitalizations for heart failure by approximately 30% and in slowing the progression of chronic kidney disease, even in patients without diabetes mellitus. The congress emphasized the need for early initiation of treatment, individualization based on organ-specific risk, and an interdisciplinary approach.

Keywords:

SGLT2 inhibitors – type 2 diabetes mellitus – heart failure – chronic kidney disease – cardiorenal protection

Sources

EASD Annual Meeting 2025. Scientific Programme and Abstracts. Vienna: European Association for the Study of Diabetes 2025. Dostupné z WWW: <https://www.easd.org>.
Herrington WG, Staplin N, Wanner C et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med 2023; 388(2): 117–127. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2204233>.
Heerspink HJ, Stefansson BV, Correa-Rotter R et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020; 383(15): 1436–1446. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2024816>.
McMurray JJ, Solomon SD, Inzucchi SE et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019; 381(21): 1995–2008. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1911303>.
Solomon SD, McMurray JJ, Claggett B et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 2022; 387(12): 1089–1098. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2206286>.